February 5, 2007:  Ipca files to DCGI - India First Investigational New Drug Application (INDA) in collaboration with Central Drug Research Institute (CDRI), Lucknow

Ipca Laboratories Limited has entered into a collaborative agreement with CDRI Lucknow to develop novel antimalarial drugs. The investigational compound CDRI-97/98 is a synthetic trioxane; a new chemical entity co-developed by CDRI and licenced to Ipca. The pre-clinical development of this compound was carried out at CDRI and Chemical Research Division of Ipca. The IND application was compiled by Medical Affairs and Clinical Research Department of Ipca and is being filed to DCGI's Office for seeking approval to conduct Phase-I (first in human) studies.

This development is a major milestone in history of Ipca as this is the first new chemical entity of Ipca. Successful development of this molecule will result in availability of new therapeutic armamentarium in treatment of resistant falciparum malaria.

Back